These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 30234904)

  • 1. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
    Mickiewicz A; Borowiec-Wolna J; Bachorski W; Gilis-Malinowska N; Gałąska R; Raczak G; Chmara M; Wasąg B; Jaguszewski MJ; Fijałkowski M; Gruchała M
    Cardiol J; 2019; 26(6):669-679. PubMed ID: 30234904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
    Drouin-Chartier JP; Tremblay AJ; Bergeron J; Lamarche B; Couture P
    Atherosclerosis; 2018 Mar; 270():26-32. PubMed ID: 29407885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017.
    Pottle A; Thompson G; Barbir M; Bayly G; Cegla J; Cramb R; Dawson T; Eatough R; Kale V; Neuwirth C; Nicholson K; Payne J; Scott J; Soran H; Walji S; Watkins S; Weedon H; Nath Datta DB
    Atherosclerosis; 2019 Nov; 290():44-51. PubMed ID: 31563836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
    Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M
    J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
    Lee WP; Datta BN; Ong BB; Rees A; Halcox J
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of lipid reduction with DALI and MONET.
    Ramlow W; Röseler E; Heigl F; Spitthöver R; Ringel J; Schmitz G; Heinzler R; Abdul-Rahman N; Leistikow F; Himmelsbach F; Schettler V; Pham J; Kozik-Jaromin J
    Atheroscler Suppl; 2017 Nov; 30():217-224. PubMed ID: 29096841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions.
    Bosch T; Gahr S; Belschner U; Schaefer C; Lennertz A; Rammo J;
    Ther Apher Dial; 2006 Jun; 10(3):210-8. PubMed ID: 16817783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
    Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
    Kayikcioglu M; Tokgozoglu L; Dogan V; Ceyhan C; Tuncez A; Kutlu M; Onrat E; Alici G; Akbulut M; Celik A; Yesilbursa D; Sahin T; Sonmez A; Ozdogan O; Temizhan A; Kilic S; Bayram F; Sabuncu T; Coskun FY; Ildizli M; Durakoglugil E; Kirilmaz B; Yilmaz MB; Yigit Z; Yildirim AB; Gedikli O; Topcu S; Oğuz A; Demir M; Yenerçağ M; Yıldırır A; Demircan S; Yilmaz M; Kaynar LG; Aktan M; Durmus RB; Gokce C; Ozcebe Oİ; Akyol TK; Okutan H; Sag S; Gul OO; Salcioglu Z; Altunkeser BB; Kuku I; Yasar HY; Kurtoglu E; Kose MD; Demircioglu S; Pekkolay Z; Ilhan O; Can LH
    Atherosclerosis; 2018 Oct; 277():341-346. PubMed ID: 30270069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
    Thiery J; Seidel D
    Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein apheresis in the management of severe hypercholesterolemia and hyperlipoproteinemia(a)-The Portuguese experience.
    Ferreira L; Palma I; Bacelar C; Queirós JA; Madureira A; Oliveira JC; Ramos MH; Cardoso H
    Transfus Apher Sci; 2018 Oct; 57(5):676-680. PubMed ID: 30287070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
    Jansen M; Banyai S; Schmaldienst S; Goldammer A; Rohac M; Hörl WH; Derfler K
    Wien Klin Wochenschr; 2000 Jan; 112(2):61-9. PubMed ID: 10703153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results.
    Bambauer R; Olbricht CJ; Schoeppe E
    Ther Apher; 1997 Aug; 1(3):242-8. PubMed ID: 10225746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.
    Dlouha D; Blaha M; Blaha V; Fatorova I; Hubacek JA; Stavek P; Lanska V; Parikova A; Pitha J
    Atheroscler Suppl; 2017 Nov; 30():128-134. PubMed ID: 29096828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.